Compare GSK plc (GSK) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Synopsys, Inc. — how do they compare? GSK plc trades at $50.28 (market cap $102.60B), while Synopsys, Inc. trades at $412.22 (market cap $78.68B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.57% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| GSK | SNPS | |
|---|---|---|
Market Cap | $102.60B | $78.68B |
Sector | Health | Technology |
52-Week High | $61.18 | $625.80 |
52-Week Low | $38.22 | $372.33 |
Enterprise Value | $123.04B | $87.04B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Synopsys (SNPS) trades at $413.78, up 0.51% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E of 94.03, P/S of 8.68) but maintains strong gross margins of 73.47%. Recent news highlights AI-driven growth from the Ansys acquisition and partnerships with AMD and Microsoft, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. Earnings growth and AI adoption in chip design are key catalysts, yet investors should monitor margin sustainability and debt levels amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
